Polyvalency of Tn (GalNAcα1→Ser/Thr) glycotope as a critical factor for Vicia villosa B4 and glycoprotein interactions  by Wu, Albert M.
Polyvalency of Tn (GalNAcK1CSer/Thr) glycotope as
a critical factor for Vicia villosa B4 and glycoprotein interactions
Albert M. Wu
Glyco-Immunochemistry Research Laboratory, Institute of Molecular and Cellular Biology, College of Medicine, Chang-Gung University, Kwei-San,
Tao-Yuan 333, Taiwan
Received 19 November 2003; revised 28 January 2004; accepted 29 January 2004
First published online 1 March 2004
Edited by Guido Tettamanti
Abstract Vicia villosa B4 (VVL-B4) is an important lectin for
detecting exposed Tn (GalNAcK1-Ser/Thr) determinants on
cancer cells. In order to elucidate the binding factors involved
in VVL-B4 and glycotope interaction, the binding properties of
this lectin were analyzed by enzyme-linked lectinosorbent and
inhibition assays. From the results, it is concluded that the most
critical factor a¡ecting VVL-B4 binding is polyvalency at the K
anomer of Gal with ^NH CH3CO at carbon-2 (Tn epitope),
which enhances the reactivity by 3.3U105 times over monova-
lent Gal. The reactivities of glycotopes can be ranked as fol-
lows: high density Tn clusterETn glycopeptides (MW6 3.0U
103)Emonomeric Tn to tri- Tn glycopeptidesFother Gal-
NAcK/L-related structural unitssGal and GalK- or L-linked
ligands, demonstrating the essential role of the polyvalency of
Tn glycotopes in the enhancement of the binding.
7 2004 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
The Tn determinant (GalNAcK-O-Ser/Thr), normally a
cryptic structure in the peptide core of O-glycoproteins
(gps), is expressed in an unmasked form in about 90% of
human carcinomas [1^3]. A direct link has been shown to exist
between carcinoma aggressiveness and the density of this anti-
gen, including extent of tissue spread and vessel invasion [4].
Therefore, the Tn determinant (GalNAcK-O-Ser/Thr) has
been considered to be the most speci¢c human tumor-associ-
ated structure [4]. The Tn antigen has been characterized us-
ing both monoclonal antibodies and plant lectins [5^7].
Among these, a plant lectin from the seeds of Vicia villosa
(VVL-B4) has been recognized as one of the most useful
probes. This lectin is a tetramer composed of two di¡erent
subunits. Three related isolectins, composed of di¡erent
amounts of the two subunits, have been puri¢ed [8]. The A4
isolectin (composed of four A subunits) is responsible for the
anti-A1 blood group activity. The B4 isolectin, which is com-
posed of four B subunits, does not agglutinate normal human
erythrocytes, but does agglutinate Tn erythrocytes. VVL-B4
also agglutinates erythrocytes expressing the Cad determinant
[9,10]. The Tn antigen is a terminal O-linked K-GalNAc res-
idue, while the Cad determinant is an O-linked chain with a
sialylated L-GalNAc. Many papers have described the binding
properties of VVL-B4 [11^16]. However, these studies were
limited to the interaction/inhibition of GalNAc-related sac-
charides [11,12], Tn monomer to tri-Tn synthetic glycopepti-
des [13], simple sugar crystal lectin binding [16], and histo-
chemical detection [17]. The recognition pro¢les with natural
glycotope clusters in macromolecules and binding factors
[18,19] have not been extensively examined. Therefore, we
characterized the binding properties of this lectin by en-
zyme-linked lectinosorbent (ELLSA) and inhibition assays us-
ing our library of ligands [20]. From the results, it is con-
cluded that ¢ve important factors are involved in VVL-B4
binding, with the con¢guration of Gal being the most essen-
tial ; the cluster form of Gal with ^NH CH3CO at carbon-2
(high density Tn cluster) enhanced the reactivity by more than
3.3U105 times over monovalent Gal. Apart from the Tn gly-
cotope, all other mammalian glycotopes reacted weakly with
VVL-B4, and the reactivities of glycotope clusters and mono-
meric glycotopes can be ranked in decreasing order as: poly-
valent TnETn glycopeptidesEmonomeric Tn to tri-Tn gly-
copeptidessGalNAcEGal, thus giving an excellent example
of a⁄nity enhancement by glycotope polyvalencies relevant to
carbohydrate^protein recognition processes.
2. Materials and methods
2.1. Glycoproteins
Tn and sialyl-Tn containing ovine, bovine, armadillo, and porcine
submandibular gps were puri¢ed according to the procedure of Tet-
tamanti and Pigman [21] and its modi¢cations [22]. Native ASG-Tn, a
salivary gp of the nine-banded armadillo containing only Tn as car-
bohydrate side chains, was isolated as described by the method of Wu
et al. [23].
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Abbreviations: Sugars: Gal, D-galactopyranose; Glc, D-glucopyra-
nose; D-Fuc, D-fucopyranose; L-Ara, L-arabinose; GalNAc, 2-acet-
amido-2-deoxy-D-galactopyranose; GlcNAc, 2-acetamido-2-deoxy-D-
glucopyranose; Man, D-mannopyranose; NeuNAc/Sialic acid, N-ace-
tylneuraminic acid; Glycoproteins (gp): HSM, hamster submaxillary
sialyl Tn gp; ASG-Tn, native Tn glycoprotein from armadillo salivary
gland; OSM, ovine submandibular glycoprotein-major; BSM, bovine
submandibular glycoprotein-major; HOC, human ovarian cyst £uid;
PSM, porcine salivary glycoprotein; THGP, Tamm^Horsfall glyco-
protein; Lectin: VVL-B4, Tn-speci¢c lectin from seeds of Vicia
villosa ; The mammalian carbohydrate structural units in glycans
used to de¢ne binding properties of VVL-B4 and expressed in paren-
theses after glycoproteins are listed in Table 2; II, GalL1C4GlcNAc;
mII, poly (multi) valent II ; ELLSA, enzyme-linked lectinosorbent
assay; Reagent: TBS-T, Tris^HCl-bu¡ered saline containing 0.05%
Tween 20
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Glycophorin A, a sialyl TK-containing gp, was prepared from the
membranes of human blood group O erythrocytes [24,25]. Asialo-
glycophorin (TK glycophorin) was prepared by mild acid hydrolysis
[21,22]. Tn-glycophorin was prepared from asialo-glycophorin by
Smith degradation [20,24].
ABH blood group active gps (e.g. Cyst MSS, Beach and Tighe)
were prepared from human ovarian cyst £uid [26^29]. Human K1-
acid gp and fetuin, which contain multi-antennary II containing N-
glycans, were purchased from Sigma Chemical (St. Louis, MO, USA).
Desialylation of sialo gps was performed by mild acid hydrolysis in
0.01 N HCl at 80‡C for 90 min and dialyzed against distilled H2O for
2 days to remove small fragments [21,22].
2.2. Sugars used for inhibition studies
Monosaccharides and oligosaccharides were purchased from Sigma
Chemical and Dextra (Berkshire, UK). Tn glycopeptides (MW6 3.0U
103) and tri-antennary GalL1C4GlcNAc glycopeptides were prepared
from asialo fetuin and asialo OSM, respectively [30,31].
2.3. Lectin
VVL-B4 was purchased from Sigma Chemical. Biotinylation of lec-
tin was performed as described by Duk et al. [20].
2.4. Lectinochemical assays
The assay was performed according to the procedures described by
Fig. 1. Binding of VVL-B4 to microtiter plates coated with serially diluted human blood group ABH and Tn active gps, sialo and asialo gps.
The amount of lectin used was 5 ng/well. Total volume of the assay was 50 Wl. A405 was recorded after 2 h incubation.
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Duk et al. [20]. The volume of each reagent applied to the plate was
50 Wl/well, and all incubations, except for coating, were performed at
room temperature. The reagents, if not indicated otherwise, were di-
luted with TBS containing 0.05% Tween 20 (TBS-T). The TBS bu¡er
or 0.15 M NaCl containing 0.05% Tween 20 was used for washing the
plate between incubations. For inhibition studies, the serially diluted
inhibitor samples were mixed with an equal volume of lectin solution
containing a ¢xed amount of VVL-B4. The control lectin sample was
diluted twofold with TBS-T. After 30 min at room temperature, the
samples were tested by the binding assay, as described by Duk et al.
[20]. The inhibitory activity was estimated from the inhibition curve
and is expressed as the amount of inhibitor (nmol/well in Table 2 and
ng in Table 3) giving 50% inhibition of the control lectin binding.
3. Results
3.1. VVL-B4^glycoform interaction
The interaction pro¢les of VVL-B4 with various gps, as
studied by a microtiter plate ELLSA, are illustrated in Fig.
1 and the maximum A405 value and the amount required for
1.5 (A405) units are shown in Table 1. Among the ligands
tested, VVL-B4 bound most strongly to polyvalent Tn con-
taining gps (asialo hamster, porcine, ovine, and bovine sub-
maxillary mucin in Fig. 1a^c and native armadillo subman-
dibular Tn gps in Fig. 1b) [18,19]. These reached absorbance
values of over 2.5 (A405) within 2 h and required less than 3.1
ng gp for 1.5 units of absorbance. VVL-B4 also reacted well
with the human Tn-glycophorin (Fig. 1d) but required 20.0 ng
of gp to reach 1.5 units of absorbance. VVL-B4 reacted poorly
with sialylated Tn containing gps (OSM, PSM, BSM, HSM in
Fig. 1a^c), TK gp (asialo human glycophorin, Fig. 1d), ABH
blood group gps (Cyst Mcdon (Ah), Cyst Beach phenol-in-
soluble (Bh), Cyst Tighe phenol-insoluble (H) ; Fig. 1e) as
well as native and asialo fetuin/human K1-acid gp (mII). These
results indicate that the unmasked polyvalent Tn glycotopes,
but not the other mammalian structures (I/II, ABH and T) are
the essential factors for VVL-B4 binding.
3.2. Inhibition of VVL-B4^glycoform interaction by mono- and
oligosaccharides
The ability of various sugar ligands to inhibit the binding of
VVL-B4 with a Tn-containing gp (asialo OSM) as measured
by ELLSA is shown in Fig. 2 and the nanomoles of ligands
required for 50% inhibition of the lectin^glycan interac-
tion are listed in Table 2. Among the monosaccharides and
oligosaccharides studied, the Tn glycopeptide fraction
(MW6 3.0U103) from ovine submandibular gp was the best
inhibitor. It was about 1.2U103, 13.3 and 3.3 times more
active than Gal, GalNAc and GalNAcK1CSer/Thr (Tn),
respectively. This fraction was about 5^28 times more
active than other GalNAc-related ligands ^ PK (GalNAcL1-
3GalK1-O-Me), S (GalNAcL1-4Gal), A (GalNAcK1-3Gal),
P (GalNAcL1-3Gal) and F (GalNAcK1-3GalNAc) ^ while
L (GalL1-4Glc), I (GalL1-3GlcNAc), II (GalL1-4GlcNAc),
E (GalK1-4Gal), TK (GalL1-3GalNAcK1-benzyl), T (GalL1-
3GalNAc), B (GalK1-3Gal) and TL (GalL1-3GalNAcL1-O-
Me) (curves 24^31) were poor inhibitors.
3.3. Inhibition of VVL-B4^glycoform interaction by various
glycoproteins
The abilities of various gps to inhibit the binding of VVL-
B4 with asialo OSM were analyzed by ELLSA and are shown
Table 1
Binding of VVL-B4 (5 ng/well) to human blood group A, B, H, P1 Lea and Leb active gps, sialo and asialo gps by ELLSAa
Graph in Fig. 1 Glycoprotein (lectin determinantsb ;
blood group speci¢city)
1.5 (A405) unit (ng) Maximum A405
Absorbance readingc Binding intensityc
Exposed polyvalent Tn gps
a Asialo HSM (Tn) 0.4 3.4 +++++
b Native ASG-Tn (Tn) 0.5 3.2 +++++
c Asialo PSM (Tn, TK, Ah, H) 1.1 2.5 +++++
b Asialo OSM (Tn) 1.7 2.9 +++++
c Asialo BSM (Tn, GlcNAcL1-3 Tn) 3.1 2.9 +++++
d Tn-glycophorin (Tn) 20.0 3.5 +++++
Cryptic Tn and other gps
b OSM (sialyl Tn, Tn) ^ 1.0 ++
c PSM (Ah, H, sialyl TK, sialyl Tn) ^ 0.8 +
c BSM (sialyl Tn, sialyl GlcNAcL1-3 Tn) ^ 0.6 +
e Cyst MSM 10% ppt (Ah, [A1]) ^ 0.2 Q
e Cyst MSS 10% 2U (Ah, [A1]) ^ 0.1 3
e Cyst 14 phenol-insoluble (Ah, [A2]) ^ 0.1 3
e Cyst Mcdon (Ah) ^ 0.1 3
e Cyst Beach phenol-insoluble (B) ^ 0.1 3
a HSM (Sialyl Tn, Tn) ^ 0 3
d Human glycophorin (sialyl TK) ^ 0 3
d Asialo human glycophorin (TK) ^ 0 3
f Human K1-acid gp (sialyl II) ^ 0 3
f Asialo human K1-acid gp (II) ^ 0 3
e Cyst Tighe phenol-insoluble (H) ^ 0 3
f Fetuin gp (sialyl II, T) ^ 0 3
f Asialo fetuin (T, II) ^ 0 3
a5 ng of biotinylated lectin was added to various gp concentrations ranging from 0.001 ng to 5 Wg.
bThe symbol in parentheses indicates the human blood group activity and/or lectin determinants [19]. Expressed in bold are: A (GalNAcK1-
3Gal); Ah (GalNAcK1-3[LFucK1-2]Gal); B (GalK1-3Gal); H (LFucK1-2Gal); T (GalL1-3GalNAc); Tn (GalNAcK1-Ser/Thr); I/II (GalL1-3/
4GlcNAc).
cThe results were interpreted according to the measured A405 after 2 h incubation as follows: +++++ (ODv 2.5), ++++ (2.5sODv 2.0), +++
(2.0sODv 1.5), ++ (1.5sODv 1.0), + (1.0sODv 0.5), Q (0.5sODv 0.2), and 3 (OD6 0.2).
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in Fig. 3. The amounts of gp required for 50% inhibition are
listed in Table 3. Among the gps tested for inhibition of in-
teraction, three Tn-containing gps (asialo OSM, native ASG-
Tn and asialo BSM) were the best (Fig. 3), requiring less than
0.6 ng to inhibit 50% of the interaction. They were up to
3.3U105, 4.4U103 and 1.5U103 times more active than Gal,
GalNAc, and Tn monomer, respectively, while the Tn glyco-
peptide fraction (MW6 3.0U103) was only 5.2 times more
active than Tn monomer (curves 1^4 vs. 10 and 11). These
results establish that polyvalency of Tn plays an important
role in VVL-B4 and gp binding. Proline-rich Tn gp (asialo
HSM, curve 4), and a low density of Tn gp (curve 5, Tn-
glycophorin, containing less than 15 Tn residues/mol) reduced
the reactivity signi¢cantly. Apart from asialo OSM and asialo
BSM, most crypto-Tn glycans and I/II-containing gps were
inactive.
Fig. 2. Inhibition of VVL-B4 binding to a Tn-containing gp (asialo OSM)-coated ELLSA plate by various saccharides. The amount of gp in
the coating solution was 10.0 ng/well. The lectin (10.0 ng/well) was pre-incubated with an equal volume of serially diluted inhibitor. The ¢nal
VVL-B4 content was 5.0 ng/well. The total volume was 50 Wl. A405 was recorded after 2 h incubation. a: Inhibition pro¢le of mammalian struc-
tural units. b: Inhibition pro¢le of monosaccharides and their derivatives.
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4. Discussion
During the past two decades, it has been established that
many multi-branched oligosaccharides exhibit a signi¢cant in-
crement in lectin binding reactivity as compared to their linear
counterparts [32], especially ‘the glycoside cluster e¡ect’ in
mammalian hepatic asialo gp receptors [33,34]. Based on the
results of this study, the concept of glycoside cluster e¡ect can
be classi¢ed into two groups: (a) the ‘multi-antennary or sim-
ple glycoside cluster e¡ect’ as in galactosides with hepatic
lectin [33,34] and tri-antennary II sequences as in a galectin
from chicken liver (CG-16) [35] or Tn glycopeptides (curve 7
in Table 3). The molecular sizes of these ligands are usually
less than 1.0U104 ; and (b) the ‘high-density polyvalent or
complex glycoside cluster e¡ect’, such as polyvalent Tn in
asialo OSM which generates an enhancement in a⁄nity with
VVL-B4 by about 3.3U105 times over Gal (curves 1 vs. 11 in
Table 3) and is about 1000 times more active than monomeric
Tn. A similar phenomenon was also observed with some ani-
mal lectins [36]. This peculiar e¡ect could be explained by a
remarkably extended sugar binding surface area formed by
the planar array of four sugar binding sites of VVL-B4 tet-
ramers, based on the model of another structurally well-
studied polyvalent ligand binding protein, the mammalian
mannose binding protein A [37]. However, the e¡ect of poly-
valencies of glycotopes on the carbohydrate^protein binding
does not always make such an important contribution. For
example, the potency in the interaction of Pseudomonas aeru-
ginosa II lectin with L-FucK1 polyvalent glycans is about as
strong as or weaker than the incremental increase by carbo-
hydrate speci¢city of monomers [38] (unpublished data).
Therefore, to obtain a solid description of the carbohydrate
speci¢cities of a lectin in order to elucidate its functional roles
and biomedical applications, the following information should
be given: (i) monosaccharide speci¢city (Gal, GalNAc,
GlcNAc, and/or Man), (ii) expression of reactivities toward
mammalian disaccharides and Tn structural units (in decreas-
ing order) [32], (iii) the most active ligand, (iv) simple multi-
valent or cluster e¡ect of carbohydrate structured unit such as
Tn glycopeptides and multi-antennary glycotopes to inhibit
binding, and (v) complex multivalent or cluster e¡ects present
in macromolecules with known glycotopes.
Based on these guidelines, we demonstrated the e¡ects of
various factors on VVL-B4 binding as follows: (a) the con¢g-
uration of Gal is essential (Table 3), (b) ^NH CH3CO at
carbon-2 of GalNAc enhances the reactivity by more than
73 times (Table 3), (c) the K-anomer of GalNAc (Tn) is
more potent than the L-anomer (GalNAcL1C) and is the
most active ligand, (d) a simple Tn cluster (Tn glycopeptide;
MW6 3.0U103 ; Table 3) can increase the reactivity up to
Table 2
Amount of various saccharides giving 50% inhibition of binding of VVL-B4 (5 ng/50 Wl) by asialo OSM (2 ng/50 Wl)a
Curve No. Curve in Fig. 2 Saccharide Quantity giving 50% inhibition (nmol) Relative potencyb
Simple Tn cluster
1 a Tn-containing glycopeptides (MW6 3.0U103) 0.3 1200.0
2 a Tri-antennary GalL1C4GlcNAc s 8.9 (10.0%) ^
Monosaccharides and their derivatives
3 b p-NO2-phenyl-K-GalNAc 1.9 189.5
4 b p-NO2-phenyl-L-GalNAc 2.3 156.5
5 b p-NO2-phenyl-K-Gal 102.0 3.5
6 b p-NO2-phenyl-L-Gal 102.0 3.5
7 b Methyl-K-GalNAc 1.2 300.0
8 b Methyl-L-GalNAc 3.5 102.9
9 b Methyl-K-Gal 80.0 4.5
10 b Methyl-L-Gal 410.0 0.9
11 a GalNAc 4.0 90.0
12 a, b Gal 360.0 1.0
13 b D-Fuc 700.0 0.5
14 b L-Ara 910.0 0.4
15 b GlcNAc 7.0U103 0.051
16 b Glc s 2.0U104 (30.0%)c ^
17 b Man s 3.0U103 (23.7%) ^
Mammalian carbohydrate structural units
18 a GalNAcK1-Ser (Tn) 1.0 360.0
19 a GalNAcL1-3GalK1-O-Me (PK) 5.0 72.0
20 a GalNAcL1-4Gal (S) 6.0 60.0
21 a GalNAcK1-3Gal (A) 8.0 45.0
22 a GalNAcL1-3Gal (P) 11.0 32.7
23 a GalNAcK1-3GalNAc (F) 28.0 12.9
24 a GalL1-4Glc (L) 540.0 0.7
25 a GalL1-3GlcNAc (I) s 148.3 (41.1%) ^
26 a GalL1-4GlcNAc (II) s 145 (17.9%) ^
27 a GalK1-4Gal (E) s 31.1 (9.3%) ^
28 a GalL1-3GalNAcK1-benzyl (TK) s 46.9 (4.6%) ^
29 a GalL1-3GalNAc (T) s 57.8 (3.4%) ^
30 a GalK1-3Gal (B) s 31.1 (1.4%) ^
31 a GalL1-3GalNAcL1-O-Me (TL) s 27.8 (0.8%) ^
aThe inhibitory activity was estimated from the inhibition curve in Fig. 2 and is expressed as the amount of inhibitor giving 50% inhibition.
Total volume 50 Wl.
bRelative potency=quantity of Gal (curve 12) required for 50% inhibition taken as 1.0/quantity of sample required for 50% inhibition.
cThe inhibitory potency of inactive saccharides is expressed as the maximum amount of sugar tested that yielded inhibition (in parentheses) be-
low 50%.
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1.1U103 times (curve 7 in Table 3), and (e) high density of Tn
is s 5.0U103 times more active than Tn monomer.
In previous studies [13,39], the binding of VVL-B4 was
shown to be independent of the density of Tn structures. Their
conclusions were based on the results of three small synthetic
Tns (one to three Tn residues) containing the glycopeptides
used as inhibitors. Their results, thus, were ¢tting within an
independent zone of the Tn density as compared with the
known pro¢le. In this study, the unrevealed part of VVL-
B4^gp binding was explored by using our developed method
and a wider range (four to 100 residues) of Tn polyvalent-
containing glycopeptides and gps from natural sources. As a
result, the e¡ect of the polyvalency on binding was detected.
Combining the results of previous reports and this study, it is
concluded that the concept of ‘polyvalency of Tn (Gal-
NacK1CSer/Thr) glycotope as a critical factor for V. villosa
B4 and gp interactions’ becomes more understandable and
valuable.
It was reported that VVL-B4 has been used to di¡erentiate
between Sd.(aþ) and Sd.(a3) Tamm^Horsfall gps (THGP)
[40]. The disaccharide structural unit (GalNAcL1C4Gal res-
idue) of Sd.(aþ) THGP was a poor inhibitor for VVL-B4
binding. However, the binding forces of THGP Sd.(aþ) and
VVL-B4 interaction can be derived from the following two
factors: (a) the amount of lectin added for the interaction
was increased 20 times and (b) the polyvalency e¡ect of Gal-
NAcL1C4Gal enhanced the reactivity. These two factors may
also explain the interaction of VVL-B4 with Cad-carrying er-
ythrocytes [9,10]. In order to establish a reliable di¡erential
binding system, it is suggested to quantify the amount of
lectin required for detecting Tn, Sd.(aþ), and Cad epitopes.
However, this is hampered by the lack of availability of re-
lated glycans and ligands.
In summary, the binding pro¢le of VVL-B4 can be
expressed in decreasing order as follows: high density of
polyvalent Tn macromolecules (MWs 1.0U105)ETn gly-
copeptides (MW6 3.0U103)Emonomeric Tn to tri-Tn gly-
copeptidessGalNAcsGalNAcL1-3GalK1-O-Me (PK), Gal-
NAcL1-4Gal (S), GalNAcK1-3Gal (A), GalNAcL1-3Gal (P),
GalNAcK1-3GalNAc (F)sGalEGalL1-4Glc (L), GalL1-
3GlcNAc (I), GalL1-4GlcNAc (II), GalK1-4Gal (E), GalL1-
3GalNAcK1-benzyl (TK), GalL1-3GalNAc (T), GalK1-3Gal
(B), GalL1-3GalNAcL1-O-Me (TL) (weak or inactive), where
polyvalency of Tn clusters plays a critical role in binding.
Glycoconjugates on the cell surface occur frequently in
clustered and polyvalent forms. Among them, many weak li-
gands, such as the binding ability of GalNAcL1C4Gal, can
be enhanced to reach a biologically signi¢cant level by poly-
valency e¡ects [40]. Therefore, this binding pro¢le has to be
updated whenever new cluster e¡ects on lectin binding are
identi¢ed. The information obtained from this study not
only facilitates understanding of VVL-B4 interaction with nat-
Fig. 3. Inhibition of VVL-B4 binding to a Tn-containing gp (asialo OSM)-coated ELLSA plate with various gps. The quantity of gp in the
coating solution was 10.0 ng/well. The quantity of lectin used for the inhibition assay was 5 ng/well. The total volume was 50 Wl. A405 was re-
corded after 2 h incubation. The amount (ng) of gp required to induce 50% inhibition was determined.
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ural cellular (polyvalent) ligands, but also explains the various
biological activities of VVL-B4 with respect to lectin^receptor
recognition processes. These special VVL-B4 binding features
also support the concept that every lectin with a unique amino
acid sequence has its own binding characteristics [19].
Acknowledgements: This work was supported by Grants from the
Chang-Gung Medical Research Project (CMRP No. 1028), Kwei-
san, Tao-yuan, Taiwan, and the National Science Council (NSC 92-
2311-B-182-005, 92-2320-B-182-045, 92-2320-B-182-046), Taipei, Tai-
wan.
References
[1] Springer, G.F. (1984) Science 224, 1198^1206.
[2] Itzkowitz, S.H., Yuan, M., Montgomery, C.K., Kjeldsen, T.,
Takahashi, H.K., Bigbee, W.L. and Kim, Y.S. (1989) Cancer
Res. 49, 197^204.
[3] Springer, G.F. (1997) J. Mol. Med. 75, 594^602.
[4] Springer, G.F. (1995) Crit. Rev. Oncogen. 6, 57^85.
[5] Hirohashi, S., Clausen, H., Yamada, T., Shimosato, Y. and Ha-
komori, S. (1985) Proc. Natl. Acad. Sci. USA 82, 7039^7043.
[6] Takahashi, H., Metoki, R. and Hakomori, S. (1988) Cancer Res.
48, 4361^4367.
[7] Nakada, H., Numata, Y., Inoue, M., Tanaka, N., Kitagawa, H.,
Funakoshi, I., Fukui, S. and Yamashina, I. (1991) J. Biol. Chem.
266, 12402^12405.
[8] Tollefsen, S.E. and Kornfeld, R. (1983) J. Biol. Chem. 258, 5165^
5171.
[9] Piller, V., Piller, F. and Cartron, J.P. (1986) J. Biol. Chem. 261,
14069^14075.
[10] Tollefsen, S.E. and Kornfeld, R. (1984) Biochem. Biophys. Res.
Commun. 123, 1099^1106.
[11] Tollefsen, S.E. and Kornfeld, R. (1983) J. Biol. Chem. 258, 5172^
5176.
[12] Piller, V., Piller, F. and Cartron, J.P. (1990) Eur. J. Biochem.
191, 461^466.
[13] Osinaga, E., Bay, S., Tello, D., Babino, A., Pritsch, O., Assemat,
K., Cantacuzene, D., Nakada, H. and Alzari, P. (2000) FEBS
Lett. 469, 24^28.
[14] Osinaga, E., Tello, D., Batthyany, C., Bianchet, M., Tavares, G.,
Duran, R., Cervenansky, C., Camoin, L., Roseto, A. and Alzari,
P. (1997) FEBS Lett. 412, 190^196.
[15] Puri, K.D., Gopalakrishnan, B. and Surolia, A. (1992) FEBS
Lett. 312, 208^212.
[16] Babino, A., Tello, D., Rojas, A., Bay, S., Osinaga, E. and Alzari,
P.M. (2003) FEBS Lett. 536, 106^110.
[17] Dabelsteen, E. (1996) J. Pathol. 179, 358^369.
[18] Wu, A.M., Song, S.C., Chen, Y.Y. and Gilboa-Garber, N. (2000)
J. Biol. Chem. 275, 14017^14024.
[19] Wu, A.M. (2003) J. Biomed. Sci. 10, 676^688.
[20] Duk, M., Lisowska, E., Wu, J.H. and Wu, A.M. (1994) Anal.
Biochem. 221, 266^272.
[21] Tettamanti, G. and Pigman, W. (1968) Arch. Biochem. Biophys.
124, 41^50.
[22] Wu, A.M. (1977) Biochem. J. 161, 37^47.
[23] Wu, A.M., Wu, J.H. and Shen, F. (1994) Biochem. Biophys. Res.
Commun. 198, 251^256.
[24] Lisowska, E., Messeter, L., Duk, M., Czerwinski, M. and Lund-
blad, A. (1987) Mol. Immunol. 24, 605^613.
[25] Wu, A.M., Kabat, E.A., Pereira, M.E., Gruezo, F.G. and Liao,
J. (1982) Arch. Biochem. Biophys. 215, 390^404.
[26] Kabat, E.A. (1956) Blood Group Substances: Their Chemistry
and Immunochemistry, pp. 135^139, Academic Press, New York.
[27] Wu, A.M., Kabat, E.A., Nilsson, B., Zopf, D.A., Gruezo, F.G.
and Liao, J. (1984) J. Biol. Chem. 259, 7178^7186.
[28] Wu, A.M. (1988) Adv. Exp. Med. Biol. 228, 351^394.
[29] Donald, A.S., Soh, C.P., Watkins, W.M. and Morgan, W.T.
(1982) Biochem. Biophys. Res. Commun. 104, 58^65.
[30] Wu, J.H., Song, S.C., Chen, Y.Y., Tsai, M.S., Kabat, E.A. and
Wu, A.M. (1998) FEBS Lett. 427, 134^138.
[31] Wu, A.M., Song, S.C., Wu, J.H., Chang, K.S. and Kabat, E.A.
(1997) Glycobiology 7, 1061^1066.
[32] Wu, A.M. and Sugii, S. (1988) Adv. Exp. Med. Biol. 228, 205^
264.
[33] Lee, R.T. and Lee, Y.C. (2000) Glycoconj. J. 17, 543^551.
[34] Lee, Y.C. (1992) FASEB J. 6, 3193^3200.
Table 3
Amounts of di¡erent gps giving 50% inhibition of binding of VVL-B4 (5 ng/50 Wl) by asialo OSM (2 ng/50 Wl)a
Curve No. Glycoprotein/glycan Quantity giving 50% inhibition (ng) Relative potencyb
1 Asialo OSM (Tn) 0.2 3.3U105
2 Native ASG-Tn (Tn) 0.4 1.6U105
3 Asialo BSM (Tn, GlcNAcL1-3Tn) 0.6 1.1U105
4 Asialo HSM (Tn) 2.0 3.2U104
5 Tn-glycophorin (Tn) 20.0 3.2U103
6 OSM (sialyl Tn, Tn) 30.0 2.2U103
7 Tn-containing glycopeptides (MW6 3.0U103) 60.9 1.1U103
8 BSM (sialyl Tn, sialyl GlcNAcL1-3Tn) 100.0 648.0
9 GalNAcK1-Ser (Tn) 308.0 210.4
10 GalNAc 884.8 73.2
11 Gal 6.5U104 1.0
12 HSM (sialyl Tn, Tn) s 277.8 (29.5%)c ^
13 Cyst Beach phenol-insoluble (B) s 277.8 (24.3%) ^
14 Cyst 14 phenol-insoluble (Ah [A2]) s 277.8 (22.7%) ^
15 Cyst MSM 10% ppt (Ah [A2]) s 277.8 (18.2%) ^
16 Asialo human K1-acid gp (mII) s 277.8 (16.3%) ^
17 Cyst Mcdon (Ah) s 277.8 (12.3%) ^
18 Cyst MSS 10% 2U (Ah [A1]) s 277.8 (10.5%) ^
19 Asialo human glycophorin (TK) s 277.8 (4.1%) ^
20 Human glycophorin (sialyl TK) s 277.8 (3.8%) ^
21 Human K1-acid gp (sialyl mII) s 277.8 (3.1%) ^
22 Cyst Tighe phenol-insoluble (H) s 277.8 (0%) ^
23 Fetuin gp (sialyl II, T) s 277.8 (0%) ^
24 Asialo fetuin (T, II) s 277.8 (0%) ^
aThe inhibitory activity was estimated from the inhibition curve in Fig. 3 and is expressed as the amount of inhibitor giving 50% inhibition.
Total volume 50 Wl.
bRelative potency=quantity of Gal (curve 11) required for 50% inhibition taken as 1.0/quantity of sample required for 50% inhibition.
cThe inhibitory potency of inactive saccharides is expressed as the maximum amount of sugar tested that yielded inhibition (in parentheses) be-
low 50%.
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